Status:

COMPLETED

Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5%

Lead Sponsor:

Hordinsky, Maria K., MD

Collaborating Sponsors:

National Alopecia Areata Foundation

Conditions:

Alopecia Areata

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the effi...

Detailed Description

We will examine how the application of Aldara Cream 5% daily for 6 months will affect the hair follicle and the inflammation present in the skin of patients with alopecia areata. In the study we will ...

Eligibility Criteria

Inclusion

  • Must be in good health.
  • No topical or systemic treatment for alopecia areata for at least 2 weeks prior to study initiation.
  • Must be at least 18 years of age and older
  • Will have to have extensive scalp alopecia areata (\>95% involvement) of less than 2 years duration.
  • Willing to refrain from other alopecia areata treatments during the course of the study.
  • Will have to agree to shampoo their scalp daily with Free and Clear shampoo. Participant in "Aldara for the Treatment of Extensive Alopecia Areata" study.

Exclusion

  • History of any illness or condition that in the opinion of the investigator might confound the results of the study or pose additional risk to the patient
  • Significant abnormalities on screening clinical evaluation.
  • Previous use of Aldara Cream 5%.
  • A history of drug or alcohol abuse.
  • Use of UV radiation including tanning beds and PUVA therapy for treatment of acne, psoriasis, or any other skin condition within 2 months prior to study initiation.
  • Use of systemic or topical glucocorticoids, corticosteroids, estrogenic, progestogenic, androgenic or antiandrogen drugs, cyclosporine, FK506 or immunotherapy with DNCB,SADBE or DCP within 6 months of study initiation.
  • Alterations in thyroid medication within 6 weeks of study initiation. Pregnant or nursing females. Not participating in the "Aldara for the Treatment of Extensive Alopecia Areata" study.

Key Trial Info

Start Date :

October 1 2000

Trial Type :

INTERVENTIONAL

End Date :

August 1 2002

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT00176943

Start Date

October 1 2000

End Date

August 1 2002

Last Update

February 14 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Minnesota

Minneapolis, Minnesota, United States, 55455